Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07476287 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Symbiotic-Lung-14: A Study to Learn About the Study Medicine Called PF08634404 in Combination With Chemotherapy in Adult Participants With Transformed Small Cell Lung Cancer

StatusRecruiting
PhasePhase 2
SponsorPfizer
Started
View on ClinicalTrials.gov ↗

Record History

  1. Trial sites expanded: 57 → 61 locations
  2. Trial sites expanded: 30 → 57 locations Primary completion date: Mar 19, 2028 to Mar 24, 2028 · Completion date: Mar 19, 2031 to Mar 24, 2031 · Eligibility criteria expanded, about 36 words · 1 more Show 4 more changesShow less
    • Primary completion date: Mar 19, 2028 to Mar 24, 2028
    • Completion date: Mar 19, 2031 to Mar 24, 2031
    • Eligibility criteria expanded, about 36 words
    • Secondary endpoints: details revised at 1 of 6 entries
  3. Trial sites expanded: 21 → 30 locationsv6
  4. Trial sites expanded: 12 → 21 locations Start date changed from estimate of May 15, 2026 to Jul 2, 2026v5 Show 1 more changeShow less
    • Start date changed from estimate of May 15, 2026 to Jul 2, 2026
  5. Trial sites expanded: 3 → 12 locationsv4
  6. Study sites: 2 to 3v3
  7. Recruitment opened Study sites: 0 to 2v2 Show 1 more changeShow less
    • Study sites: 0 to 2
  8. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Pfizer
433 trials monitored
See 31 trials at risk
Lung Cancer
4,057 trials monitored
See 217 trials at risk
Small Cell Lung Cancer
540 trials monitored
See 31 trials at risk
This study is being done to learn more about a new medicine called PF-08634404. The study team wants to understand how well PF-08634404 works when given alone or with chemotherapy . Chemotherapy is a type of cancer treatment that uses medicines to destroy cancer cells or stop them from growing. The study is for adults with Transformed Small Cell Lung Cancer (T-SCLC ). T SCLC is a rare lung cancer that happens when one type of lung cancer changes into a more aggressive type after treatment stops working. To join the study, participants must meet the following conditions: * Are aged 18 years or older * Diagnosed with T-SCLC and have not received treatment for this type of lung cancer (a single cycle of chemotherapy may be permitted) * Prior diagnosis of epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer treated with tyrosine kinase inhibitors (TKIs) * Have healthy organs based on medical tests and are in good physical condition After joining the study, adults will be given chemotherapy in addition to the study medicine. After this combination treatment is finished, the study medicine will be continued alone. Adults will receive the treatment through IV infusions (medicine given directly into a vein). All treatments will be done at clinical study sites, where a trained medical team will monitor adults during and after each visit.
Trial Details
NCT Number NCT07476287
Lead Sponsor Pfizer
Conditions Small Cell Lung Cancer, Small Cell Lung Cancer ( SCLC ), Transformed Small Cell Lung Cancer, Lung Neoplasms, Carcinoma, Small Cell Lung, Small Cell Cancer Of The Lung
Enrollment 40 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov